Conversion from cyclosporin A to sirolimus retards the progression of chronic allograft nephropathy in the long term in a rat kidney transplantation model

Journal of International Medical Research

Volumn 37, Issue 5, 2009, Pages 1396-1410

  He, Z ^a,b   Chen, Lizhong ^a   Qiu, J ^a   Li, J ^a   Zhao, D ^a   Chen, G ^a   Wang, C ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Calcineurin inhibitors; Chronic allograft nephropathy; Cyclosporin A; Rapamycin; Rat kidney transplantation model; Sirolimus

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; RAPAMYCIN;

ALLOTRANSPLANTATION; ANIMAL; ARTICLE; CHRONIC DISEASE; DISEASE MODEL; ENZYME IMMUNOASSAY; FISCHER 344 RAT; GENETICS; GRAFT REJECTION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LEWIS RAT; MALE; METABOLISM; PATHOLOGY; PROTEINURIA; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CHRONIC DISEASE; CYCLOSPORINE; DISEASE MODELS, ANIMAL; GRAFT REJECTION; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; PROTEINURIA; RATS; RATS, INBRED F344; RATS, INBRED LEW; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIROLIMUS; TIME; TRANSPLANTATION, HOMOLOGOUS;

EID: 77649222583     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/147323000903700514     Document Type: Article

References (42)

1. Chapman JR: Longitudinal analysis of chronic allograft nephropathy: clinicopathologic correlations. Kidney Int Suppl 2005; 68: S108-S112.
2. Halloran PF, Melk A, Barth C: Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 1999; 10: 167-181.
3. Joosten SA, van Kooten C, Paul LC: Pathogenesis of chronic allograft rejection. Transpl Int 2003; 16: 137-145.
4. Nankivell BJ, Borrows RJ, Fung CL, et al: The natural history of chronic allograftnephropathy. N Engl J Med 2003; 349: 2326-2333.
5. MacDonald AS: Impact of immunosuppressive therapy on hypertension. Transplantation 2000; 70 (11 suppl): S70-S76.
6. Kasiske BL, Snyder JJ, Gilbertson D, et al: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185.
7. Suwelack B, Gerhardt U, Hohage H: Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4: 655-662.
8. Weir MR, Blahut S, Drachenburg C, et al: Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004; 24: 379-386.
9. Chung J, Kuo CJ, Crabtree GR, et al: Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992; 69: 1227-1236.
10. Price DJ, Grove JR, Calvo V, et al: Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 1992; 257: 973-977.
11. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372: 570-573.
12. Dominguez J, Mahalati K, Kiberd B, et al: Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 2000; 70: 1244-1247.
13. Egidi MF, Cowan PA, Naseer A, et al: Conversion to sirolimus in solid organ transplantation: a single-center experience. Transplant Proc 2003; 35(3 suppl): 131S-137S.
14. Bumbea V, Kamar N, Ribes D, et al: Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20: 2517-2523.
15. Watson CJ, Firth J, Williams PF, et al: A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005; 5: 2496-2503.
16. Diamond JR, Tilney NL, Frye J, et al: Progressive albuminuria and glomerulosclerosis in a rat model of chronic renal allograft rejection. Transplantation 1992; 54: 710-716.
17. Hancock WH, Whitley WD, Tullius SG, et al: Cytokines, adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts. Transplantation 1993; 56: 643-650.
18. DiJoseph JF, Fluhler E, Armstrong J, et al: Therapeutic blood levels of sirolimus (rapamycin) in the allografted rat. Transplantation 1996; 62: 1109-1112.
19. Jiang H, Wynn C, Pan F, et al: Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. Transplantation 2002; 73: 1808-1817.
20. Lutz J, Huang H, Deng M, et al: The effect of FK778 on the progression of chronic allograft nephropathy in a rat model. Transplantation 2007; 83: 741-746.
21. Racusen LC, Solez K, Colvin RB, et al: The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
22. Ninova D, Covarrubias M, Rea DJ, et al: Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-β1 and α-smooth muscle actin. Transplantation 2004; 78: 338-344.
23. O'Connell TX, Mowbray JF: Arterial intimal thickening produced by alloantibody and xenoantibody. Transplantation 1973; 15: 262-263.
24. Hamar P, Szab A, Müller V, et al: The involvement of activated T cells and growth-factor production in the early and late phase of chronic kidney allograft nephropathy in rats. Transpl Int 2002; 15: 446-454.
25. Noris M, Azzollini N, Pezzotta A, et al: Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. J Am Soc Nephrol 2001; 12: 1937-1946.
26. Viklický O, Zou H, Müller V, et al: SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000; 69: 497-502.
27. Schmid C, Heemann U, Azuma H, et al: Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts. Transplantation 1995; 60: 729-733.
28. Akselband Y, Harding MW, Nelson PA: Rapamycin inhibits spontaneous and fibroblast growth factor B-stimulated proliferation of endothelial cells and fibroblasts. Transplant Proc 1991; 23: 2833-2836.
29. Marx SO, Jayaraman T, Go L, et al: Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995; 76: 412-417.
30. Mohacsi PJ, Tuller D, Hullinger B, et al: Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997; 16: 484-492.
31. Schuurman HJ, Pally C, Weckbecker G, et al: SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc 1999; 31: 1024-1025.
32. Somasundaram R, Schuppan D: Type I, II, III, IV, V, and VI collagens serve as extracellular ligands for the isoforms of platelet-derived growth factor (AA, BB, and AB). J Biol Chem 1996; 271: 26884-26891.
33. Shihab FS, Tanner AM, Shao Y, et al: Expression of TGF-β1 and matrix proteins is elevated in rats with chronic rejection. Kidney Int 1996; 50: 1904-1913.
34. Mannon RB, Kopp JB, Ruiz P, et al: Chronic rejection of mouse kidney allografts. Kidney Int 1999; 55: 1935-1944.
35. Muchaneta-Kubara EC, el Nahas AM: Myofibroblast phenotypes expression in experimental renal scarring. Nephrol Dial Transplant 1997; 12: 904-915.
36. Ahuja SS, Shrivastav S, Danielpour D, et al: Regulation of transforming growth factor-β1 and its receptor by cyclosporine in human T lymphocytes. Transplantation 1995; 60: 718-723.
37. Wolf G, Thaiss F, Stahl RA: Cyclosporine stimulates expression of transforming growth factor-β in renal cells. Possible mechanism of cyclosporines antiproliferative effects. Transplantation 1995; 60: 237-241.
38. Shihab FS, Bennett WM, Yi H, et al: Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-β1 in chronic cyclosporine nephrotoxicity. Am J Transplant 2003; 3: 1550-1559.
39. Dodge IL, Demirci G, Strom TB, et al: Rapamycin induces transforming growth factor-β production by lymphocytes. Transplantation 2000; 70: 1104-1106.
40. Shihab FS, Bennett WM, Yi H, et al: Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-β1. Transplantation 2004; 77: 683-686.
41. Hariharan S, Johnson CP, Bresnahan BA, et al: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612.
42. Stallone G, Infante B, Schena A, et al: Rapamycin for treatment of chronic allograft nephropathy in renal transplant patiens. J Am Soc Nephrol 2005; 16: 3755-3762.